Introduction
Lipoprotein lipase (LPL) is an extracellular enzyme on the vascular endothelial surface that degrades circulating triglycerides in the bloodstream. These triglycerides are embedded in verylow-density lipoproteins (VLDL) and chylomicrons traveling through the bloodstream. The role of lipoprotein lipase is significant in understanding the pathophysiology of type onefamilialdyslipidemias, or hyperchylomicronemia, and its clinical manifestations. LPL also plays an essential role in understanding the cardiac pharmacology of fibratesas a class of medications and in managing patients withhigh levels of serum triglycerides. This review will explore lipoprotein lipase's function, pathophysiology, and clinical relevance.[1]
Molecular Level
The structure of lipoprotein lipase is similar to the enzymes in the lipase family and comprises two distinct regions. LPL has an N-terminal domain with a lipolytic active site and a C-terminaldomain. These two regions attach using a peptide link. Recent x-ray crystallography and biochemical experiments have provided more structural evidence revealing that lipoprotein lipase can be active as a monomer.[2][3]Also, Cryo-EM studies have shown that the inactive form oflipoprotein lipase is a polymer.[4]
Function
Lipoprotein lipase is an enzyme that degrades circulating triglycerides in the bloodstream. These triglycerides are embedded in verylow-density lipoproteins (VLDL) and chylomicrons traveling through the bloodstream. Lipoprotein lipase is an extracellular enzyme on the vascular endothelial surface, anchored to capillary walls. This enzyme is predominantly in adipose tissue, muscle, and heart tissue but not in the liver, as the liver has hepatic lipase. Lipoprotein functions to convert triglycerides to fatty acids and glycerol.
Fatty acids liberated from the triglycerides are then used for storage in adipose tissue or fuel in skeletal or cardiac muscle. Lipoprotein lipase requires apolipoprotein-CII, a cofactor for lipoprotein lipase, which is carried by a chylomicron as well as by very low-density lipoprotein and intermediate-density lipoproteins (IDL), for activation. Lipoprotein lipase will shrink the chylomicrons by removing the fatty acids from triglycerides, which are transferred to adipocytes and skeletal muscle. At the same time, the liver takes up the chylomicron remnants via receptor-mediated endocytosis.[1]
Pathophysiology
The pathophysiology of lipoprotein lipase is evident in familial dyslipidemias (specifically type one) or hyperchylomicronemia. Hyperchylomicronemia is an autosomal recessive genetically inherited disease in which there is a significant increase in levels of triglycerides, >1000, such that the plasma of these patients has a milky appearance. There are also significantly increased chylomicron levels in these individuals' blood.[5]
In both type one familial dyslipidemia or hyperchylomicronemia, there is severe LPL dysfunction; this is because of LPL deficiency and LPL co-factor deficiency, or apolipoprotein C2 deficiency, which is necessary for activation of lipoprotein lipase. LPL typically removes triglycerides from chylomicrons; if this process does not function, initial triglyceride breakdown cannot occur. Therefore, triglycerides will build up in the serum, and chylomicrons will grow very large as they are full of triglycerides,which are not undergoing removal.[6]
Patients with hyperchylomicronemia present with recurrent pancreatitis, enlarged liver, and xanthomas because of a lack of triglyceride removal from chylomicrons and increased serum triglycerides and chylomicrons levels. This buildup eventually leads to triglyceride accumulation in the pancreas, in the liver, and deposits on the skin, causing these clinical manifestations. Xanthomas occur because of plaques of lipid-laden histiocytes, as macrophages in the bloodstream endocytose excess serum triglycerides. Clinically, xanthomas appear as skin bumps or along the eyelids of patients with high serum lipid levels.[7]
Elevated triglycerides can cause acute pancreatitis, which may involve increased plasma chylomicrons. These chylomicrons can obstruct capillaries, and this may cause decreased blood flow and, ultimately, ischemia. When vessel damage occurs, this can cause pancreatic lipases to have access to serum triglycerides. Pancreatic lipases may break down these triglycerides, releasing triglyceride breakdown products, including free fatty acids. This increase in free fatty acids can injure the tissue of the pancreas leading to pancreatitis.[7]
Treatment for type 1 familial dyslipidemia or hyperchylomicronemia is a verylow-fat diet. With careful monitoring of diet, patients often have normal lifespans. Additionally, with tight dietary lipid control, patients have no apparent increased risk for atherosclerosis.Orlistat is a medication that can also improve hyperchylomicronemia by decreasing the risk of pancreatitis; it is a pancreatic lipase inhibitor given before meals.[8]
Clinical Significance
Lipoprotein is clinically significant in cardiac pharmacology, specifically in cholesterol management. Fibrates, such as fenofibrate, bezafibrate, and gemfibrozil, work by activating peroxisome proliferator-activated receptor alpha (PPAR-alpha) and upregulating lipoprotein lipase. Activation of PPAR alpha leads to gene transcription modification. Modified gene transcription leads to increased lipoprotein lipase activity. PPAR-alpha activity also increases the oxidation of fatty acids in the liver, which leads to decreased levels of verylow-density lipoprotein. Ultimately, this leads to reduced serum triglyceride levels, as they increase hydrolysis of VLDL and chylomicron triglycerides via lipoprotein lipase. Thus, fibrates are indicated for patients with highlyelevated levels of triglycerides.
Fibrates decrease serum LDL mildly by reducing VLDL; however, statins are the first-line therapy for lowering LDL. Fibrates induce high-density lipoprotein (HDL) synthesis, mildly increasing serum HDL by activating apolipoprotein A1 and apolipoprotein A2, creating nascent HDLs. Clinically, fibrates are primarily indicated for decreasing blood triglyceride levels, and they are the most effective class of drugs for this function. Side effects of fibrates include cholesterol gallstones, as they increase the cholesterol content of bile.
Fibrates may also cause rhabdomyolysis, and the risk of myopathy is higher when combined with statins. Fibrates can also cause increased levels of liver enzymes such as alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), and gamma-glutamyl transpeptidase (GGT). Fibrates are usually combined with other cholesterol-lowering treatments as they increase low-density lipoproteins (LDL).[9]
Clinically, LPL plays a significant role in the progression of atherosclerosis. LPL is a component in atherosclerotic lesions, which derive from macrophages. Furthermore, patients with advanced atherosclerosis were found to have elevated LPL mass and activity in their post-heparin plasma. LPL contributes to atherogenic lipoprotein formation. LPL acts on chylomicrons and VLDL to hydrolyze triglycerides from them and form VLDL remnants and chylomicron remnants. VLDL remnants and chylomicron remnants are composed of a high concentration of cholesterol esters and then get incorporated into macrophages. LPL creates free fatty acids, and macrophages then re-esterify them, accumulating cholesterol esters in macrophages, causing macrophages to transform into foam cells. LPL catalyzed the conversion of VLDL to Intermediate density lipoproteins (IDL), which hepatic lipases then convert to low-density lipoprotein (LDL). Foam cells also form when macrophages incorporate oxidized LDL via their scavenger receptor in the vascular endothelium.[10]
References
- 1.
Mead JR, Irvine SA, Ramji DP. Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med (Berl). 2002 Dec;80(12):753-69. [PubMed: 12483461]
- 2.
Beigneux AP, Allan CM, Sandoval NP, Cho GW, Heizer PJ, Jung RS, Stanhope KL, Havel PJ, Birrane G, Meiyappan M, Gill JE, Murakami M, Miyash*ta K, Nakajima K, Ploug M, Fong LG, Young SG. Lipoprotein lipase is active as a monomer. Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6319-6328. [PMC free article: PMC6442593] [PubMed: 30850549]
- 3.
Arora R, Nimonkar AV, Baird D, Wang C, Chiu CH, Horton PA, Hanrahan S, Cubbon R, Weldon S, Tschantz WR, Mueller S, Brunner R, Lehr P, Meier P, Ottl J, Voznesensky A, Pandey P, Smith TM, Stojanovic A, Flyer A, Benson TE, Romanowski MJ, Trauger JW. Structure of lipoprotein lipase in complex with GPIHBP1. Proc Natl Acad Sci U S A. 2019 May 21;116(21):10360-10365. [PMC free article: PMC6534989] [PubMed: 31072929]
- 4.
Gunn KH, Roberts BS, Wang F, Strauss JD, Borgnia MJ, Egelman EH, Neher SB. The structure of helical lipoprotein lipase reveals an unexpected twist in lipase storage. Proc Natl Acad Sci U S A. 2020 May 12;117(19):10254-10264. [PMC free article: PMC7229681] [PubMed: 32332168]
- 5.
Falko JM. Familial Chylomicronemia Syndrome: A Clinical Guide For Endocrinologists. Endocr Pract. 2018 Aug;24(8):756-763. [PubMed: 30183397]
- 6.
Blom DJ, O'Dea L, Digenio A, Alexander VJ, Karwatowska-Prokopczuk E, Williams KR, Hemphill L, Muñiz-Grijalvo O, Santos RD, Baum S, Witztum JL. Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study. J Clin Lipidol. 2018 Sep-Oct;12(5):1234-1243.e5. [PubMed: 30318066]
- 7.
Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007 Apr 10;176(8):1113-20. [PMC free article: PMC1839776] [PubMed: 17420495]
- 8.
Blackett P, Tryggestad J, Krishnan S, Li S, Xu W, Alaupovic P, Quiroga C, Copeland K. Lipoprotein abnormalities in compound heterozygous lipoprotein lipase deficiency after treatment with a low-fat diet and orlistat. J Clin Lipidol. 2013 Mar-Apr;7(2):132-9. [PubMed: 23415432]
- 9.
Okopień B, Bułdak Ł, Bołdys A. Benefits and risks of the treatment with fibrates--a comprehensive summary. Expert Rev Clin Pharmacol. 2018 Nov;11(11):1099-1112. [PubMed: 30328735]
- 10.
Kobayashi J, Mabuchi H. Lipoprotein lipase and atherosclerosis. Ann Clin Biochem. 2015 Nov;52(Pt 6):632-7. [PubMed: 25995285]
Disclosure: Yasaman Pirahanchi declares no relevant financial relationships with ineligible companies.
Disclosure: McDamian Anoruo declares no relevant financial relationships with ineligible companies.
Disclosure: Sandeep Sharma declares no relevant financial relationships with ineligible companies.
